## Guillaume Jondeau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2442842/publications.pdf

Version: 2024-02-01

59 7,912 32 h-index

60 60 7566
all docs docs citations times ranked citing authors

59

g-index

#	Article	IF	Citations
1	The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics, 2010, 47, 476-485.	3.2	1,677
2	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	2.2	1,114
3	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
4	Multimodality Imaging of Diseases of the Thoracic Aorta in Adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 2015, 28, 119-182.	2.8	500
5	TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nature Genetics, 2012, 44, 916-921.	21.4	319
6	Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). European Heart Journal, 2019, 40, 3848-3855.	2.2	209
7	Comparison of Clinical Presentations and Outcomes Between Patients With <i>TGFBR2</i> and <i>FBN1</i> Mutations in Marfan Syndrome and Related Disorders. Circulation, 2009, 120, 2541-2549.	1.6	203
8	Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. Heart, 2014, 100, 126-134.	2.9	190
9	<i>LOX</i> Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. Circulation Research, 2016, 118, 928-934.	4.5	180
10	Marfan Sartan: a randomized, double-blind, placebo-controlled trial. European Heart Journal, 2015, 36, 2160-2166.	2.2	179
11	Central Pulse Pressure Is a Major Determinant of Ascending Aorta Dilation in Marfan Syndrome. Circulation, 1999, 99, 2677-2681.	1.6	178
12	Aortic Event Rate in the Marfan Population. Circulation, 2012, 125, 226-232.	1.6	165
13	International Registry of Patients Carrying <i>TGFBR1</i> or <i>TGFBR2</i> Mutations. Circulation: Cardiovascular Genetics, 2016, 9, 548-558.	5.1	145
14	Nomograms for Aortic Root Diameters in Children Using Two-Dimensional Echocardiography. American Journal of Cardiology, 2010, 105, 888-894.	1.6	140
15	Current aspects of the spectrum of acute heart failure syndromes in a realâ€ife setting: the OFICA study. European Journal of Heart Failure, 2013, 15, 465-476.	7.1	135
16	Cardiovascular manifestations in men and women carrying a FBN1 mutation. European Heart Journal, 2010, 31, 2223-2229.	2.2	133
17	B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal, 2009, 30, 2186-2192.	2.2	128
18	Aortic Disease Presentation and Outcome Associated With <i>ACTA2</i> Mutations. Circulation: Cardiovascular Genetics, 2015, 8, 457-464.	5.1	117

#	Article	IF	CITATIONS
19	From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta. Cardiovascular Research, 2018, 114, 578-589.	3.8	114
20	MFAP5 Loss-of-Function Mutations Underscore the Involvement of Matrix Alteration in the Pathogenesis of Familial Thoracic Aortic Aneurysms and Dissections. American Journal of Human Genetics, 2014, 95, 736-743.	6.2	110
21	Marfan syndrome. Nature Reviews Disease Primers, 2021, 7, 64.	30.5	99
22	Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. European Journal of Human Genetics, 2009, 17, 1121-1128.	2.8	82
23	Characterization of <sup>18</sup> F-Fluorodeoxyglucose Uptake Pattern in Noninfected Prosthetic Heart Valves. Circulation: Cardiovascular Imaging, 2017, 10, e005585.	2.6	75
24	Association of modifiers and other genetic factors explain Marfan syndrome clinical variability. European Journal of Human Genetics, 2018, 26, 1759-1772.	2.8	73
25	Clinical relevance of genotype–phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genetics in Medicine, 2021, 23, 1296-1304.	2.4	63
26	Prognosis Factors in Probands With an FBN1 Mutation Diagnosed Before the Age of 1 Year. Pediatric Research, 2011, 69, 265-270.	2.3	59
27	The clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. Human Molecular Genetics, 2015, 24, 2764-2770.	2.9	57
28	Study of phenotype evolution during childhood in Marfan syndrome to improve clinical recognition. Genetics in Medicine, 2014, 16, 246-250.	2.4	45
29	False lumen embolization in chronic aortic dissection promotes thoracic aortic remodeling at midterm follow-up. Journal of Vascular Surgery, 2019, 70, 710-717.	1.1	45
30	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6, 62-69.	3.1	45
31	Genetics of Thoracic Aortic Aneurysms. Current Atherosclerosis Reports, 2012, 14, 219-226.	4.8	40
32	Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With MarfanÂSyndrome. Journal of the American College of Cardiology, 2020, 75, 843-853.	2.8	38
33	Optimising Aortic Endovascular Repair in Patients with Marfan Syndrome. European Journal of Vascular and Endovascular Surgery, 2020, 59, 577-585.	1.5	35
34	Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. European Heart Journal, 2022, 43, 1901-1916.	2.2	32
35	Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease. Heart, 2021, 107, 1704-1709.	2.9	29
36	European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet Journal of Rare Diseases, 2019, 14, 264.	2.7	23

#	Article	IF	CITATIONS
37	Comparative assessment of ascending aortic aneurysms in Marfan patients using ECG-gated computerized tomographic angiography versus trans-thoracic echocardiography. International Journal of Cardiology, 2015, 184, 22-27.	1.7	21
38	Systems pharmacology–based integration of human and mouse data for drug repurposing to treat thoracic aneurysms. JCI Insight, 2019, 4, .	5.0	21
39	Loeys–Dietz syndrome is a specific phenotype and not a concomitant of any mutation in a gene involved in TGF-β signaling. Genetics in Medicine, 2014, 16, 641-642.	2.4	18
40	Risk of Ascending Aortic Aneurysm in Patients With Autosomal Dominant Polycystic Kidney Disease. American Journal of Cardiology, 2019, 123, 482-488.	1.6	16
41	Incidence of cardiovascular events and risk markers in a prospective study of children diagnosed with Marfan syndrome. Archives of Cardiovascular Diseases, 2020, 113, 40-49.	1.6	12
42	Quantifying the Genetic Basis of Marfan Syndrome Clinical Variability. Genes, 2020, 11, 574.	2.4	11
43	Beta-Blockers in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 654-656.	4.1	8
44	Skeletal evolution in Marfan syndrome: growth curves from a French national cohort. Pediatric Research, 2018, 83, 71-77.	2.3	6
45	Reference Expression Profile of Three FBN1 Transcript Isoforms and Their Association with Clinical Variability in Marfan Syndrome. Genes, 2019, 10, 128.	2.4	6
46	Staged hybrid repair of type II thoracoabdominal aneurysms. Journal of Vascular Surgery, 2021, 74, 20-27.	1.1	6
47	Coronavirus disease vaccination in heart failure: No time to waste. Archives of Cardiovascular Diseases, 2021, 114, 434-438.	1.6	6
48	Marfan Syndrome Variability: Investigation of the Roles of Sarcolipin and Calcium as Potential Transregulator of FBN1 Expression. Genes, 2018, 9, 421.	2.4	4
49	Marfan sartan saga, episode X. European Heart Journal, 2020, 41, 4188-4190.	2.2	4
50	Inhibition of HIPK2 Alleviates Thoracic Aortic Disease in Mice With Progressively Severe Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2483-2493.	2.4	4
51	Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: An international retrospective cohort study. European Journal of Medical Genetics, 2022, 65, 104503.	1.3	4
52	Response by Mathieu et al to Letter Regarding Article, "Characterization of 18 F-Fluorodeoxyglucose Uptake Pattern in Noninfected Prosthetic Heart Valves― Circulation: Cardiovascular Imaging, 2017, 10,	2.6	3
53	eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN). Orphanet Journal of Rare Diseases, 2021, 16, 164.	2.7	3
54	The VASCERN European Reference Network: An overview. European Journal of Medical Genetics, 2022, 65, 104420.	1.3	3

#	Article	IF	CITATIONS
55	Marfan Syndrome. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	2
56	Preliminary Experience With Custom Made Hourglass Shaped Thoracic Stent Grafts for Endovascular Thoracic Aortic Coarctation Repair in Adults. European Journal of Vascular and Endovascular Surgery, 2021, 62, 1000-1001.	1.5	2
57	Is physical activity a future therapy for patients with Marfan syndrome?. Orphanet Journal of Rare Diseases, 2022, 17, 46.	2.7	2
58	Non-Dissecting Distal Aortic and Peripheral Arterial Aneurysms in Patients With Marfan Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, 827357.	2.4	2
59	Is Transesophageal Echocardiography Needed before Hospital Discharge in Patients after Bentall Surgery?. Journal of the American Society of Echocardiography, 2017, 30, 52-58.	2.8	1